A Phase Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Patients With Previously Untreated Advanced Pancreatic Cancer.
Study Status
Closed to Enrollment
Study Description
The purpose of this study is to test whether different doses of the the drug 90Y-hPAM4 are safe to give in combination with gemcitabine in patients with previously untreated pancreatic cancer.
Disease Status and/or Stage
Untreated Advanced Pancreatic Cancer
Sponsor
Immunomedics, Inc.
Key Eligibility
- Men and women age 18 and older
- Diagnosed with pancreatic cancer
- Stage III (locally advanced, unresectable) or Stage IV (metastatic) disease, including patients who underwent surgery but had incomplete resections
- Treatment naive (no prior chemotherapy, radiotherapy, or investigational drugs for pancreatic cancer)
- Additional eligibility criteria discussed when you contact the study team
Principal Investigator
Contact
- Gina Mileo, RN
- (212) 746-5430
- [email protected]
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]
